These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 23782077

  • 1. Iron (III) isomaltoside 1000.
    Mace TA, Syed A, Bhandari S.
    Expert Rev Hematol; 2013 Jun; 6(3):239-46. PubMed ID: 23782077
    [Abstract] [Full Text] [Related]

  • 2. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
    Birgegård G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M.
    Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
    [Abstract] [Full Text] [Related]

  • 3. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
    Ziedan A, Bhandari S.
    Trials; 2019 Apr 04; 20(1):194. PubMed ID: 30947751
    [Abstract] [Full Text] [Related]

  • 4. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
    Wikström B, Bhandari S, Barany P, Kalra PA, Ladefoged S, Wilske J, Thomsen LL.
    J Nephrol; 2011 Apr 04; 24(5):589-96. PubMed ID: 21240875
    [Abstract] [Full Text] [Related]

  • 5. Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial.
    Gybel-Brask M, Seeberg J, Thomsen LL, Johansson PI.
    Transfusion; 2018 Apr 04; 58(4):974-981. PubMed ID: 29424441
    [Abstract] [Full Text] [Related]

  • 6. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia.
    Kalra PA, Bhandari S, Saxena S, Agarwal D, Wirtz G, Kletzmayr J, Thomsen LL, Coyne DW.
    Nephrol Dial Transplant; 2016 Apr 04; 31(4):646-55. PubMed ID: 26250435
    [Abstract] [Full Text] [Related]

  • 7. A prospective observational study of effectiveness and safety of iron isomaltoside in patients with chronic renal failure and iron deficiency anemia
.
    Biggar P, Leistikow F, Walper A.
    Clin Nephrol; 2016 Dec 04; 86 (2016)(12):310-318. PubMed ID: 27737531
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients With Chronic Heart Failure and Iron Deficiency.
    Charles-Edwards G, Amaral N, Sleigh A, Ayis S, Catibog N, McDonagh T, Monaghan M, Amin-Youssef G, Kemp GJ, Shah AM, Okonko DO.
    Circulation; 2019 May 21; 139(21):2386-2398. PubMed ID: 30776909
    [Abstract] [Full Text] [Related]

  • 15. Use of intravenous iron supplementation in chronic kidney disease: an update.
    Macdougall IC, Geisser P.
    Iran J Kidney Dis; 2013 Jan 21; 7(1):9-22. PubMed ID: 23314137
    [Abstract] [Full Text] [Related]

  • 16. NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease.
    Kalra PA, Bhandari S, Spyridon M, Davison R, Lawman S, Mikhail A, Reaich D, Pritchard N, McCafferty K, Moore J.
    BMC Nephrol; 2020 Dec 10; 21(1):539. PubMed ID: 33302891
    [Abstract] [Full Text] [Related]

  • 17. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications.
    Jahn MR, Andreasen HB, Fütterer S, Nawroth T, Schünemann V, Kolb U, Hofmeister W, Muñoz M, Bock K, Meldal M, Langguth P.
    Eur J Pharm Biopharm; 2011 Aug 10; 78(3):480-91. PubMed ID: 21439379
    [Abstract] [Full Text] [Related]

  • 18. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.
    Bhandari S, Kalra PA, Kothari J, Ambühl PM, Christensen JH, Essaian AM, Thomsen LL, Macdougall IC, Coyne DW.
    Nephrol Dial Transplant; 2015 Sep 10; 30(9):1577-89. PubMed ID: 25925701
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.